• Guanze Intelligent Medical expects a loss attributable to owners of up to RMB 45 million for H1 ended June 30, 2026.
• That compares with profit attributable to owners of about RMB 3.4 million a year earlier.
• Lower gross profit expected as sales mix shifts toward lower-margin imaging film, imaging cloud services; software sales declined.
• Costs rose on higher depreciation, increased R&D spending, share-based payment expenses tied to February 2026 share-award vesting.
• Interim results for the period are scheduled for publication on Aug. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guanze Intelligent Medical Information Industry Holding Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300713), on August 26, 2026, and is solely responsible for the information contained therein.